Impact of Sustained Virologic Response on Glycemic Control Among Diabetic Patients With Hepatitis C Virus Related Liver Disease

Hepatitis c Clinical Trial

Official title:

Impact of Sustained Virologic Response on Glycemic Control Among Diabetic Patients With Hepatitis C Virus Related Liver Disease

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03591783
• Other study ID #: HCVDM
• Status: Not yet recruiting
• Start date: August 2018
• Est. completion date: December 2019

Study information

• Verified date: July 2018
• Source: Assiut University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Hepatitis C virus (HCV) is a major cause of chronic liver disease. The World Health Organization has reported that 170 million people are chronically infected with HCV globally. The highest prevalence of HCV infection worldwide exists in Egypt (15%); 90% of infection among Egyptian patients is due to genotype 4

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 140
• Est. completion date: December 2019
• Est. primary completion date: November 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Chronic HCV infection will be diagnosed based on positive testing for serum HCV RNA and anti-HCV Ab.

• Diagnosis of type 2 DM will depend on fasting level of serum glucose more than 126 mg/dl and/or serum level of HbA1c more than 6.5 % on oral hypoglycemic therapy.

Exclusion Criteria:

• Chronic hepatitis due to causes other than HCV infection

• Coinfection with HBV infection

• Hepatocellular carcinoma

• Child C stage of liver cirrhosis.

• Patients with type I diabetes mellitus.

• Cardiopulmonary diseases.

• Major illness.

• Patient receiving corticosteroids.

• Patient refused consent.

Related Conditions & MeSH terms

• Hepatitis
• Hepatitis A
• Hepatitis C
• Liver Diseases

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the percentage of patients with glycemic control	Exploring the impact of achieving SVR by directly acting antiviral drugs on glycemic control among diabetic patients with HCV infection.	3 months